^
    3ms
    Examination of the potential clinical application of 5DEX-0509R, the tumor macrophage-targeting nanomedicine. (PubMed, Cytokine)
    To solve this, we have developed dextran-based TAM targeting activator conjugate (D-TAC) technology which successfully uses tumor-associated macrophages (TAMs) to deliver the TLR7 agonist DSP-0509...In this study, we compared the anti-tumor effects of EIK1001 and 5DEX-0509R, and analyzed its unique immune reaction against tumors to evaluate whether 5DEX-0509R is suitable for further clinical study...We also found that 5DEX-0509R synergistically suppresses tumors with oxaliplatin by changing M2 macrophages that cause oxaliplatin to become resistant to antitumor M1 macrophages. In addition, 5DEX-0509R caused a rapid but not sustained cytokine elevation in both rats and dogs. We believe 5DEX-0509R is worth pursuing for clinical trials.
    Journal
    |
    CD4 (CD4 Molecule)
    |
    oxaliplatin • EIK1001 • guretolimod (DSP-0509)
    4ms
    KEYNOTE-G04: Safety and Efficacy of EIK1001-006 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. (clinicaltrials.gov)
    P2/3, N=740, Not yet recruiting, Eikon Therapeutics
    New P2/3 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • EIK1001
    11ms
    BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, Eikon Therapeutics | Trial primary completion date: Mar 2024 --> Aug 2024 | Trial completion date: Mar 2024 --> Aug 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • EIK1001
    11ms
    BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Eikon Therapeutics | Trial completion date: Mar 2024 --> Jul 2024 | Trial primary completion date: Mar 2024 --> Jul 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Tecentriq (atezolizumab) • EIK1001
    1year
    A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=70, Recruiting, Eikon Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • EIK1001
    1year
    BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Eikon Therapeutics | Trial primary completion date: Dec 2023 --> Mar 2024
    Trial primary completion date • Combination therapy • Metastases
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Tecentriq (atezolizumab) • EIK1001
    1year
    BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, Eikon Therapeutics | Trial primary completion date: Dec 2023 --> Mar 2024
    Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • EIK1001
    1year
    A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=70, Not yet recruiting, Eikon Therapeutics
    New P2 trial • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • EIK1001
    over1year
    BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Eikon Therapeutics | Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Tecentriq (atezolizumab) • EIK1001
    over1year
    BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, Eikon Therapeutics | Trial completion date: Dec 2022 --> Mar 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • EIK1001
    over1year
    BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors (clinicaltrials.gov)
    P2, N=1, Completed, Eikon Therapeutics | Active, not recruiting --> Completed | N=100 --> 1 | Trial completion date: Jan 2023 --> May 2023 | Trial primary completion date: Jul 2022 --> Apr 2023
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    EIK1001
    over2years
    BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Birdie Biopharmaceuticals HK Limited | Trial primary completion date: Jul 2022 --> Dec 2022
    Trial primary completion date • Combination therapy
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Tecentriq (atezolizumab) • EIK1001
    3years
    BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Birdie Biopharmaceuticals HK Limited | Trial primary completion date: Jan 2022 --> Jul 2022
    Trial primary completion date • Combination therapy
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Tecentriq (atezolizumab) • EIK1001
    over3years
    BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, Birdie Biopharmaceuticals HK Limited | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed • Combination therapy
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Tecentriq (atezolizumab) • EIK1001
    over3years
    BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab (clinicaltrials.gov)
    P1, N=50, Recruiting, Birdie Biopharmaceuticals HK Limited | Trial completion date: Jan 2022 --> Dec 2022 | Trial primary completion date: Jul 2021 --> Jan 2022
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2 (Interleukin 2) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Tecentriq (atezolizumab) • EIK1001